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results between FFR ‑guided and iFR ‑guided re‑
vascularization strategies in patients with bor‑
derline coronary stenosis.4,5 However, the mea‑
surement of iFR requires an access to a dedicat‑
ed console, which is not available in every cathe‑
terization laboratory. Moreover, there are no ran‑
domized trials comparing iFR ‑based management 
of patients with intermediate ‑grade stenosis with 
medical therapy. Data supporting the use of iFR 
to assess ambiguous left main disease are also 
lacking.1 Thus, FFR remains the current standard 
INTRODUCTION When evidence of ischemia 
is not available, coronary pressure–derived frac‑
tional flow reserve (FFR) or instantaneous wave‑
‑free ratio (iFR) is recommended to assess the he‑
modynamical significance of intermediate ‑grade 
stenosis (typically 40%–90% stenosis).1 Hemody‑
namic relevance is defined as an FFR of 0.8 or low‑
er or an iFR lower than 0.9, but the FFR thresh‑
old of 0.75 is also useful to define more severe 
ischemia that is of prognostic relevance.2,3 Re‑

















BACKGROUND Achievement of maximal hyperemia is mandatory for an accurate calculation of fractional 
flow reserve (FFR), and it is obtained with adenosine administered either as an intravenous infusion 
or intracoronary bolus.
AIMS The aim of this study was to compare the infusion of adenosine with intracoronary adenosine 
bolus dose escalation in the optimal assessment of peak FFR.
METHODS We enrolled consecutive patients with borderline coronary lesions that were assessed by FFR 
with the use of intracoronary adenosine bolus (100 µg, 200 µg, 400 µg, and 600 µg) and intravenous 
infusion of 140 µg/kg/min and 280 µg/kg/min. The FFR values obtained by the 2 different routes of 
administration were assessed and compared.
RESULTS A total of 50 patients with 125 borderline coronary artery lesions were enrolled. The mean 
(SD) physiologic severity of coronary artery stenosis was as follows: 0.82 (0.09) for intravenous adenosine 
infusion at 140 µg/kg/min; 0.81 (0.09) for intravenous adenosine infusion at 280 µg/kg/min; as well as 
0.83 (0.09) for an intracoronary adenosine bolus of 100 µg, 200 µg, 400 µg, and 600 µg each. There was 
a strong linear correlation between FFR values obtained with 140‑µg/kg/min adenosine infusion and 
intracoronary bolus injection of adenosine at a dose of 100 µg, 200 µg, 400 µg, and 600 µg (r = 0.99, 
r = 0.99, r = 0.99, r = 0.99, respectively, P <0.001 for all).
CONCLUSIONS The values of FFR achieved with an intracoronary bolus of adenosine are very similar, but 
not identical, to those obtained using intravenous adenosine administration. The values may vary between 
escalating doses of intracoronary boluses and intravenous infusion.
O R I G I N A L  A R T I C L E
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a cardiac reference university center with more 
than 1500 FFR assessments performed before. 
For the femoral venous administration of ad‑
enosine, a 6‑F venous sheath with a sidearm 
was used. The infusion system was filled with 
adenosine to exclude the washout period of 
the saline. A launcher coronary guide catheter 
(Medtronic, Minneapolis, Minnesota, United 
States) without side holes, the s5/s5i console, 
and the Verrata pressure guide wire (Philips 
Volcano Corporation, San Diego, California, 
United States) were used in all cases. Data ac‑
quisition included electrocardiographic signal 
recording. After intracoronary nitrates (300 µg) 
and acquisition of coronary angiograms, aor‑
tic pressure (Pa) and intracoronary distal pres‑
sure (Pd) were recorded in the following pat‑
tern: first, the pressure wire was zeroed and 
equalized, and its correct equalization (mean 
[SD] Pd/Pa ratio, 1.00 [0.01]) was confirmed 
during a 10‑second acquisition in the ascend‑
ing aorta in each case. Then, the pressure sen‑
sor was positioned distal to the index stenosis, 
and the guiding catheter was flushed with sa‑
line and disengaged from the coronary ostium. 
Baseline pressures were recorded for at least 20 
seconds before inducing hyperemia.
Adenosine administration through a femo‑
ral vein at a rate of 140 or 280 µg/kg/min for 
a minimum of 3 minutes and pressure wire 
pullback maneuver to check for pressure drift 
were mandatory. Each borderline lesion was as‑
sessed in the same way each time. First, an ad‑
enosine infusion through the  femoral vein 
at 140 µg/kg/min was performed. We repeat‑
ed these steps for the femoral vein adenosine 
infusion at 280 µg/kg/min. In the same pres‑
sure recording, the bookmarks for core labora‑
tory analyses were placed: 1) when adenosine in‑
fusion started; 2) when the pullback maneuver 
started; and 3) when the pressure sensor reached 
the tip of the guiding catheter. If a Pd / Pa ratio 
of less than 0.99 or more than 1.01 at the cathe‑
ter tip was documented, the protocol mandated 
a repeat assessment. After waiting for the wash‑
out of adenosine and the return of the Pd / Pa ra‑
tio to its baseline value, the guiding catheter was 
again flushed with saline and multiple intracoro‑
nary adenosine boluses (100 µg, 200 µg, 400 µg, 
and 600 µg) were administered. Each bolus was 
followed by a flush of saline and then disengage‑
ment of the guiding catheter from the coronary 
ostium. Each bolus was administered at least 1 
minute after the previous one (in all cases un‑
til pressure curves returned to baseline values). 
The measurement of FFR was performed con‑
tinuously after bolus administration. The time 
of stable hyperemia was assessed, along with 
the FFR value. Each subsequent bolus of ade‑
nosine was administered at least 1 minute af‑
ter the previous one (in all cases until pressure 
curves returned to baseline values). All boluses 
of care for the functional assessment of lesion 
severity in patients with intermediate stenosis.
Importantly, the induction of maximal hy‑
peremia is mandatory for an accurate calcula‑
tion of FFR.6 Maximal hyperemia is most com‑
monly achieved with adenosine given either 
as an intracoronary bolus or intravenous in‑
fusion. Intracoronary bolus administration is 
more challenging as it requires stable intubation 
of the guiding catheter in the coronary ostium 
and a careful assessment of short ‑lasting hyper‑
emia. On the other hand, intravenous infusion 
of adenosine provides more stable and predict‑
able hyperemia. However, it requires addition‑
al venous access and a larger amount of adenos‑
ine; therefore, it is associated with higher costs, 
more frequent occurrence of systemic adverse ef‑
fects, and, finally, it may be more time consum‑
ing.7 An optimal algorithm for the induction of 
maximal hyperemia remains a subject of debate, 
with no clear advice from current guidelines on 
myocardial revascularization. Thus, it is gener‑
ally left at the discretion of the operator.
The aim of this study was to compare an intra‑
venous infusion of adenosine with intracoronary 
adenosine bolus dose escalation for the assess‑
ment of peak FFR, as well as to develop an op‑
timal algorithm for maximal hyperemia induc‑
tion for FFR assessment in the catheterization 
laboratory.
METHODS This was a prospective study on 
consecutive patients between 18 and 90 years 
of age, with stable angina and angiographical‑
ly intermediate stenosis (>40% diameter ste‑
nosis by visual assessment) in a major epicar‑
dial coronary artery, who were scheduled for 
FFR. Baseline clinical data of patients were col‑
lected. Patients with acute myocardial infarc‑
tion or contraindications to adenosine were 
excluded. Ethics approval was granted from 
the institutional ethics review board, and all 
patients gave written informed consent. Coro‑
nary angiography was performed with the stan‑
dard femoral or radial approach based on in‑
dividual operator preferences. All procedures 
were performed by experienced operators in 
WHAT’S NEW?
Achievement of maximal hyperemia is mandatory for an accurate calculation of 
fractional flow reserve (FFR), and it is most commonly achieved with adenosine 
given either as an intravenous infusion or intracoronary bolus. Intravenous 
infusion of adenosine requires larger amounts of adenosine; therefore, it is 
associated with higher costs, more frequent occurrence of systemic adverse 
effects, and, finally, may be more time consuming. The values of FFR may vary 
between escalating doses of intracoronary boluses. There might be no need for 
increasing an adenosine bolus dose from 400 µg to 600 µg. However, there seems 
to be a grey zone (0.81–0.83) for FFR assessed with boluses, which, in selected 
cases, may indicate the use of intravenous infusion to confirm the results.
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during intravenous adenosine infusion, the min‑
imum hyperemic Pd / Pa ratio might develop 
before stabilization of hyperemia. Hence, con‑
forming to its original validation,8 core labo‑
ratory analyses included a thorough review of 
pressure recordings to confirm that the FFR was 
calculated: 1) after initiation of adenosine in‑
fusion; 2) within stable hyperemia; and 3) be‑
fore the pullback maneuver. Stable hyperemia 
was defined as the plateau in the mean Pa after 
stabilization of changing hemodynamics fol‑
lowing the initiation of adenosine infusion and 
before the pullback maneuver.7 If a plateau was 
not clearly observed, stable hyperemia was then 
defined as the period of pressure recording in 
which no further systematic fall in Pa was ob‑
served, following the initiation of adenosine in‑
fusion but before the initiation of the pullback.7 
Within stable hyperemia, the minimum Pd / Pa 
ratio was then labeled as FFR.
Core laboratory analyses included an evalua‑
tion of pressure waveforms to confirm that none 
of the following exclusion criteria were pres‑
ent: inappropriate normalization of the pres‑
sure wire (Pd / Pa ratio <0.99 or >1.01), electro‑
cardiogram artifacts or significant arrhythmias 
in the first 20 seconds of the recording, loss of 
Pa or Pd signals at any point during the record‑
ing, automatic calculation pitfalls (eg, identi‑
fication of FFR during ectopic beats, Pa or Pd 
noise, and wire whipping artifacts), dampen‑
ing of Pa or Pd waveforms, pressure drift low‑
er than 0.99 or higher than 1.01, and absence of 
electrocardiogram or pressure ‑pullback record‑
ing. The core laboratory also assessed the time 
to reaction defined as a time point from the be‑
ginning of adenosine infusion to initial drop 
of the Pd / Pa ratio, as well as the time to peak 
hyperemia defined as the time from the begin‑
ning of adenosine infusion to the lowest stable 
Pd / Pa value.
Quantitative coronary angiography was 
performed by an independent core laborato‑
ry analyst blinded to the results of FFR. Using 
the guide catheter for calibration and an edge 
detection system (CAAS 5.7 QCA system, Pie 
Medical, Maastricht, the Netherlands), the ref‑
erence vessel diameter and minimum lumen di‑
ameter were measured, and the percent diame‑
ter stenosis was calculated.
Statistical analysis Categorical variables were 
expressed as number of patients (percentage). 
Continuous variables were expressed as mean 
(SD). Nonnormally distributed data were reported 
as median (interquartile range [IQR]). Agreement 
among tested methods was assessed by Bland‑Alt‑
man plots and 95% limits of agreement. All tests 
were 2‑tailed, and a P value of less than 0.05 was 
considered significant. All statistical analyses 
were performed using STATISTICA 12.0 (StatSoft 
Inc., Tulsa, Oklahoma, United States).
were divided by saline flush and administration 
of intracoronary nitrates (300 µg). We prepared 
the drug with a dilution so that all doses could 
be administered with a 5‑cc syringe.
The FFR was experimentally and clinically 
validated under conditions of maximum and 
stable hyperemia7 and was automatically cal‑
culated by a software (ver. 2.4.1.2723, Volca‑
no, Philips Volcano, Rancho Cordova, Califor‑
nia, United States) as the minimum Pd / Pa ra‑
tio found in the pressure recording. However, 
TABLE 1 Study population (n = 50) and procedural data
Patients Value
Age, y, mean (SD) 66 (9.3) 
Male sex, n (%) 36 (72)
Height, cm, mean (SD) 169.9 (7.9)
Weight, kg, mean (SD) 80.4 (13.3)
Body mass index, kg/m2, mean (SD) 27.8 (3.7)
Arterial hypertension, n (%) 50 (100)
Diabetes mellitus, n (%) 28 (56)
Previous myocardial infarction, n (%) 26 (52)
Previous PCI, n (%) 24 (48)
Previous CABG, n (%) 0 (0)
Peripheral arterial disease, n (%) 2 (4)
Chronic obstructive pulmonary disease, n (%) 1 (2)
Previous stroke / TIA, n (%) 0 (0)
Hyperlipidemia, n (%) 50 (100)
Smoking, n (%) 20 (40)
Serum creatinine, μmol/l, mean (SD) 91.1 (19.4)
LVEF, %, mean (SD) 52.8 (8.1)
Heart rate, bpm, mean (SD) 71.5 (9.7)
Angina symptoms – CCS class, n (%) I 6 (12)
II 40 (80)
III 4 (8)




Access, n (%) Radial 35 (70)
Femoral 15 (30)
Number of assessed vessels, median (IQR) 3 (2–4)
Scheduled treatment, n (%) Conservative 21 (42)
PCI 23 (46)
CABG 6 (12)
Abbreviations: CABG, coronary artery bypass grafting; CCS, Canadian Cardiovascular Society; IQR, 
interquartile range; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PCI, 
percutaneous coronary intervention; TIA, transient ischemic attack
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coronary angiography. The left anterior descend‑
ing artery was the most commonly interrogat‑
ed vessel (36.8%).
Procedural data Procedural success was 
100% for advancing the pressure wire distally 
to the stenosis. There were no procedure ‑related 
complications. The distribution of the FFR val‑
ues in the study is shown in FIGURE 1. In general, 
patients had coronary stenoses of intermediate 
angiographic severity (mean [SD] diameter ste‑
nosis, 44.2 [11.7] mm by qualitative angiograph‑
ic assessment). Adenosine caused an asymp‑
tomatic transient third ‑degree atrioventricu‑
lar block in 5.8% of patients. Chest pain occurred 
in 13.6% of patients. On the basis of FFR assess‑
ment, 42% of patients were scheduled for con‑
servative treatment, 46% were treated with per‑
cutaneous coronary intervention (PCI), and 12% 
were scheduled for bypass surgery. In patients 
who had undergone FFR ‑guided PCI, the mean 
(SD) FFR after the procedure was 0.87 (0.02) (me‑
dian, 0.87 [IQR, 0.86–0.9]).
Functional flow reserve findings and analy-
sis The mean (SD) physiologic severity of cor‑
onary artery stenosis was 0.82 (0.09) (medi‑
an, 0.83; [IQR, 0.77–0.88]) when assessed with 
femoral vein adenosine infusion at 140 µg/kg/
min, and 0.82 (0.1) (median, 0.83 [IQR, 0.76–
0.88]) when assessed with femoral vein ade‑
nosine infusion at 280 µg/kg/min. The mean 
(SD) physiologic severity for an  intracoro‑
nary bolus of 100 µg was 0.83 (0.09) (median, 
0.84 [IQR, 0.78–0.9]); of 200 µg, 0.83 (0.09) (me‑
dian, 0.84 [IQR, 0.78–0.9]); of 400 µg, 0.83 (0.09) 
RESULTS Study population Fifty patients 
with 125 borderline coronary artery lesions were 
enrolled. The baseline characteristics of patients 
and lesions are presented in TABLES 1 and 2. Over‑
all, the mean (SD) age was 66.0 (9.3) years, and 
72% of patients were male. All patients present‑
ed with stable angina that was an indication for 
TABLE 2 Lesion characteristics
Lesions (n = 125) Value
LAD, n (%) 48 (38.4)
Dg, n (%) 11 (8.8)
Cx, n (%) 32 (25.6)
Mg, n (%) 9 (7.2)
RCA, n (%) 25 (20)
Quantitative coronary angiography results (n = 125) Value
Lesion length, mm, mean (SD) 21.7 (14)
RVD, mm, mean (SD) 2.6 (0.6)
MLD, mm, mean (SD) 1.4 (0.4)
DS, %, mean (SD) 44.2 (11.7)
Eccentric lesion, n (%) 67 (53.6)
Moderate / severe tortuosity, n (%) 52 (41.6)
Irregular contours, n (%) 11 (9.2)
Moderate / severe calcifications, n (%) 49 (40.8)
Ostial lesion, n (%) 11 (9.2)
Abbreviations: Cx, circumflex artery; Dg, diagonal branch; DS, diameter stenosis; LAD, left anterior 
descending artery; LMCA, left main coronary artery; Mg, marginal branch; MLD, minimal lumen 
diameter; RCA, right coronary artery; RVD, reference vessel diameter






















5 15 25 35 45 55 65 7510 20 30 40 50 60 70 80







FIGURE 1 Distribution of the fractional flow reserve (A) and percent diameter stenosis (B) values in the study population 
Abbreviations: FFR, fractional flow reserve; others see TABLE 1
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(SD), 6.2 (1.3) seconds (median, 6 [IQR, 5–7] sec‑
onds) for 200‑µg bolus; mean (SD), 7.6 (1.6) sec‑
onds (median, 8 [IQR, 6–9] seconds) for 400‑µg 
bolus; and mean (SD), 9.6 (2.2) seconds (median, 
10 [IQR, 8–11] seconds) for 600‑µg bolus. Per‑
centage of functionally significant lesions ac‑
cording to different methods of adenosine ad‑
ministration is presented in FIGURE 2. The mean 
FFR values for femoral vein adenosine infusion 
at 140 µg/kg/min and 280 µg/kg/min as well as 
for intracoronary adenosine boluses of 100 µg, 
200 µg, 400 µg, and 600 µg are shown in FIGURE 3. 
There was a strong linear correlation between 
FFR values obtained from 140 µg/kg/min fem‑
oral vein infusion and intracoronary adenos‑
ine bolus of 100 µg, 200 µg, 400 µg, and 600 µg 
(r = 0.99, P <0.001 for all; FIGURE 4).
Additionally, we performed a paired differ‑
ence test comparing 140 µg/kg/min femoral 
vein infusion with an intracoronary bolus of 
100 µg, 200 µg, 400 µg, and 600 µg in terms 
of FFR values and found numerically higher 
values for boluses, with a mean difference of 
0.008 for 600‑µg bolus (95% CI, –0.01 to –0.006; 
P <0.0001), 0.008 for 400‑µg bolus (95% CI, 
–0.01 to –0.006; P <0.0001), 0.01 for 200‑µg bo‑
lus (95% CI, –0.012 to –0.007; P <0.0001), and 
0.015 for 100‑µg bolus (95% CI, –0.016 to –0.01; 
P <0.0001).
Moreover, we compared differences in FFR 
values obtained from escalating intracoronary 
adenosine boluses between each other. The mean 
FFR difference between boluses was as follows: 
100 µg vs 200 µg, 0.0034 (95% CI, 0.002–0.004; 
P <0.0001); 100 µg vs 400 µg, 0.005 (95% CI, 
0.004–0.006; P <0.0001); 100 µg vs 600 µg, 
0.0055 (95% CI, 0.004–0.007; P <0.0001); 200 
µg vs 400 µg, 0.0017 (95% CI, 0.001–0002; 
P <0.0001); 200 µg vs 600 µg, 0.0022 (95% CI, 
0.001–0.003; P <0.0001); and 400 µg vs 600 µg, 
0.0005 (95% CI –0.0006 to –0.001; P = 0.08).
DISCUSSION The results of the study identi‑
fied the optimal adenosine administration and 
dose for the reliable assessment of coronary FFR 
in evaluating the hemodynamic severity of coro‑
nary stenosis. Intravenous infusion and escalat‑
ing intracoronary boluses of adenosine showed 
a close, but not identical, agreement of FFR val‑
ues after achieving maximal stable hyperemia 
and no systematic direction of bias was evi‑
dent from the Bland–Altman analysis. Howev‑
er, there seems to be a grey zone for FFR assessed 
with boluses, which, in selected cases, may indi‑
cate the use of intravenous infusion to confirm 
the results. On the basis of our results, we pro‑
pose that FFR values of 0.81 to 0.83 achieved 
with intracoronary adenosine boluses should be 
confirmed with an infusion of adenosine in or‑
der to obtain absolutely maximal stable hyper‑
emia and true FFR values.
(median, 0.84 [IQR, 0.78–0.9]); and of 600 µg, 
0.83 (0.09) (median, 0.83 [IQR, 0.77–0.89]). Data 
are presented in FIGURE 3.
The time from initiation of adenosine infusion 
to beginning of pressure gradient drop was mon‑
itored and was shorter when measured during 
the 280‑µg/kg/min femoral vein infusion com‑
pared with the 140‑µg/kg/min infusion (mean 
[SD], 24 [10] seconds; median, 20 [IQR, 17–28] 
seconds vs mean [SD], 31 [14] seconds; median, 
28 [IQR, 21–37] seconds; P <0.001).
The time from initiation of adenosine infusion 
to maximal stable hyperemia was shorter when 
assessed during the 280‑µg/kg/min femoral 
vein infusion compared with the 140‑µg/kg/min 
infusion (mean [SD], 36 [13] seconds; median, 
33 [IQR, 27–40] vs mean [SD], 49 [19] seconds; 
median, 46 [IQR, 35–58]; P <0.001).
The time from saline flush after intracoronary 
adenosine bolus injection to maximal stable hy‑
peremia was longer depending on the dose of ad‑
enosine used: mean (SD), 4.5 (1) seconds (medi‑































IC 100 μg IC 200 μg IC 400 μg Femoral 
140 μg
IC 600 μg Femoral 
280 μg
FFR ≤0.80   FFR ≤0.75   
FIGURE 2 Percentage of functionally significant lesions according to different methods of 
adenosine administration  
Abbreviations: IC, intracoronary; others, see FIGURE 1
FIGURE 3 Mean (SD) fractional flow reserve values of adenosine intracoronary boluses of 100 
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400 µg were associated with significantly low‑
er peak FFR values. However, we found that 
the FFR values achieved after 400 µg and 600 µg 
did not differ between each other, so there might 
be no need to increase the adenosine dose af‑
ter a 400‑µg bolus. This finding remains in con‑
trast to the results obtained by de Luca et al,19 
who showed that high doses of intracoronary 
adenosine (up to 720 µg) increased the sensi‑
tivity of FFR in the detection of hemodynami‑
cally relevant coronary stenosis.
Our study presents a  comprehensive ap‑
proach directly comparing different doses of 
adenosine administered as intracoronary boluses 
(100 µg, 200 µg, 400 µg, and 600 µg) with intra‑
venous adenosine infusion (140 µg/kg/min and 
280 µg/kg/min) for 2 FFR cutoff values, name‑
ly, 0.80 and 0.75. According to current guide‑
lines, hemodynamic significance of the lesion 
is confirmed by FFR of 0.80 or lower. However, 
the FFR threshold of 0.75 is also useful to define 
Intravenous infusion of adenosine has been 
the gold standard method for obtaining hyper‑
emia for FFR measurement,6,9 -15 and it can in‑
duce hyperemia with more reliable hyperemic 
efficacy than intracoronary bolus injection.16 -18 
Moreover, intravenous adenosine may result in 
more stable vasodilation and therefore may be 
more appropriate for tandem or diffuse lesion 
assessment. However, it requires an addition‑
al procedure for venous access, which may in‑
crease the risk of vascular complications and 
is not so convenient to use in transradial ap‑
proach. Therefore, in the era of radial approach 
as a common access for coronary angiography 
and intervention, an increasing frequency of in‑
tracoronary bolus of adenosine for FFR assess‑
ment has been noted. Intracoronary bolus can 
generate adequate and sufficiently stable coro‑
nary hyperemia, similar to a central venous in‑
fusion. In our study, escalating doses of an in‑
tracoronary bolus of adenosine from 100 µg to 
FIGURE 4 Correlation of fractional flow reserve values between 140 µg/kg/min femoral vein adenosine infusion and intracoronary bolus of adenosine 
(A – 100 µg; B – 200 µg; C – 400 µg; D – 600 µg)  
Abbreviations: see FIGURE 1
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300 μg, and 600 μg and intravenous adminis‑
tration of 140 μg/kg/min and 200 μg/kg/min, 
and concluded that an intracoronary bolus dose 
exceeding 300 μg can be equal to or more effec‑
tive than an intravenous infusion of adenosine in 
achieving maximum hyperemia when calculating 
the FFR (with a cutoff FFR value again of 0.8).22
It was reported that intravenous adminis‑
tration of adenosine was better in inducing hy‑
peremia than intracoronary bolus in some pa‑
tients.16,17 In our study, we compared intracoro‑
nary adenosine bolus injection to intravenous 
infusion and found numerically higher values 
(0.008‑0.015) for boluses. Therefore, when suf‑
ficient hyperemia is doubtful during intracoro‑
nary bolus of adenosine, especially with FFR val‑
ues of 0.81 to 0.83, the results should be con‑
firmed with adenosine venous infusion (FIGURE 5).
Our study has several limitations. The FFR 
procedures were performed by 2 experienced 
operators at a single center, but interobserver 
variability was not assessed. Patients with os‑
tial lesions of the right coronary artery or left 
main coronary artery as well as tandem lesions 
were not enrolled. We did not have any cross‑
overs in the study.
In conclusion, FFR values achieved with in‑
tracoronary boluses of adenosine are very sim‑
ilar, but not identical, to those obtained using 
intravenous adenosine administration. The val‑
ues of FFR may vary between escalating doses of 
intracoronary boluses and intravenous infusion. 
more severe ischemia that is of prognostic rel‑
evance and is thus more convincing to support 
revascularization, even in high ‑risk lesions and 
patient subsets.2,3 Escalating doses of intracoro‑
nary boluses as well as intravenous infusion of 
adenosine resulted in numerically higher rate of 
achieving significant FFR values, especially for 
the cutoff value of 0.75. In the study by de Luca 
et al,19 the authors compared escalating adenos‑
ine boluses with only one dose of intravenous ad‑
enosine infusion and tested only one cutoff FFR 
value (0.8). In a study by Schlundt et al,20 114 pa‑
tients with an intermediate degree of stenosis 
on coronary angiography were included. Two 
FFR assessments were performed during an in‑
tracoronary bolus injection (40 μg and 80 μg) 
and compared with continuous intravenous in‑
fusion of adenosine (140 μg/kg/min). They con‑
cluded that bolus injection of adenosine showed 
identical FFR results obtained with intravenous 
infusion while requiring less time. The doses 
were again tested only for a cutoff FFR value of 
0.8. Khashaba et al21 assessed borderline coro‑
nary lesions for ischemia only with one intra‑
coronary bolus of adenosine (150 μg) and com‑
pared it with intravenous adenosine infusion 
over 3 minutes at a dose of 140 μg/kg/min. Their 
results suggested that intracoronary adenosine 
might be an alternative to intravenous adenos‑
ine with a cutoff FFR value of 0.8 recognized as 
significant. López ‑Palop et al22 used intracor‑
onary adenosine bolus doses of 60 μg, 180 μg, 
Ostial left main coronary artery disease 
Ostial right coronary artery disease
Sequential lesions requiring pressure wire pullback
Unstable position of the guiding catheter in the coronary ostium 
YES
Intravenous infusion of adenosine
140 µg/kg/min
NO
Intracoronary bolus of adenosine dose 
escalation (100, 200, 400 µg)a




Peak FFR = 0.81–0.83 Peak FFR = 0.81–0.83
Intravenous infusion of
adenosine 280 µg/kg/min
 FIGURE 5 Suggested algorithm for maximal hyperemia induction with intracoronary boluses or infusion of adenosine for 
fractional flow reserve assessment 
a If peak fractional flow reserve is below or equals 0.80 with 2 consecutive boluses, accept peak fractional flow reserve value.
Abbreviations: see FIGURE 1
O R I G I N A L  A R T I C L E  Intracoronary versus intravenous adenosine administration for FFR 617
20 Schlundt C, Bietau C, Klinghammer L, et al Comparison of intracoronary ver-
sus intravenous administration of adenosine for measurement of coronary frac-
tional flow reserve. Circ Cardiovasc Interv. 2015; 8.







There might be no need for increasing adenosine 
bolus dose from 400 µg to 600 µg.
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